文献速递炎症性肠病

免疫介导炎症性疾病患者新冠疫苗接种的血清学应答:系统综述与荟萃分析

Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis.
PubMed 文献 · Gastroenterology · 2021-09-29

该系统综述与荟萃分析检索截至2021年8月1日的观察性研究,纳入25项研究共5360例免疫介导炎症性疾病(IMID)患者。结果显示,mRNA疫苗接种1剂和2剂后血清学应答率分别为73.2%(95%CI 65.7%-79.5%)和83.4%(95%CI 76.8%-88.4%);抗CD20治疗与较低应答率相关(P<.001),抗TNF治疗亦呈较低应答趋势(P=.058);与对照相比,IMID患者2剂mRNA疫苗后达到血清学应答的可能性更低(OR 0.086,95%CI 0.036-0.206,P<.001)。

要点

  • IMID患者mRNA疫苗接种2剂后血清学应答率为83.4%,低于对照人群。
  • 抗CD20治疗与较低血清学应答率显著相关(P<.001)。
  • 建议IMID患者尽快完成mRNA疫苗全程接种,并支持第三剂加强策略。

核心结论

  • IMID患者对mRNA新冠疫苗的血清学应答降低,建议尽快完成全程接种并支持第三剂策略。

研究设计与样本

  • 系统综述与荟萃分析,检索截至2021年8月1日的观察性研究,纳入25项研究共5360例IMID患者。

主要发现

  • mRNA疫苗1剂后血清学应答率为73.2%(95%CI 65.7%-79.5%,6项研究)。
  • mRNA疫苗2剂后血清学应答率为83.4%(95%CI 76.8%-88.4%,17项研究)。
  • 荟萃回归显示抗CD20治疗与较低应答率相关(P<.001),抗TNF治疗呈较低应答趋势(P=.058)。
  • IMID患者2剂mRNA疫苗后血清学应答可能性低于对照(6项研究;OR 0.086,95%CI 0.036-0.206,P<.001)。

关键数值与推荐

  • mRNA疫苗1剂后血清学应答率73.2%(95%CI 65.7%-79.5%)。
  • mRNA疫苗2剂后血清学应答率83.4%(95%CI 76.8%-88.4%)。
  • IMID患者与对照2剂mRNA疫苗后应答比较OR 0.086(95%CI 0.036-0.206,P<.001)。

临床怎么用

  • IMID患者接受mRNA疫苗时应尽快完成全程接种,不延迟。
  • 支持为IMID患者提供第三剂mRNA疫苗加强。

局限性

  • 腺病毒载体或灭活疫苗应答的研究数量不足,无法评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Patients with immune-mediated inflammatory diseases (IMIDs) have an increased risk of coronavirus disease 2019 (COVID-19), primarily attributed to the use of immunosuppressive drugs such as glucocorticoids, which may attenuate the response to vaccines. This meta-analysis assessed the serologic response to COVID-19 vaccination in patients with IMIDs. METHODS: Electronic databases were searched on August 1, 2021, for observational studies. Data extracted included reference population, medications, vaccination, and proportion of patients achieving a serologic response. RESULTS: The analysis included 25 observational studies (5360 patients). Most of the studies used messenger RNA (mRNA) vaccines (BNT162b2, mRNA-1273), with a small number of studies including other types of vaccines (AZD1222, CoronaVac, BBV152, Ad26.COV2.S). Serologic response after 1 dose (6 studies) and 2 doses (17 studies) of mRNA vaccine were 73.2% (95% confidence interval [CI], 65.7%-79.5%) and 83.4% (95% CI, 76.8%-88.4%), respectively. On meta-regression, anti-CD20 therapy was associated with lower response rates (P < .001) and anti-tumor necrosis factor therapy also showed a trend toward lower response rates (P = .058). Patients with IMIDs were less likely to achieve a serologic response compared with controls after 2 doses of mRNA vaccine (6 studies; odds ratio, 0.086; 95% CI, 0.036-0.206; P < .001). There were not enough studies to assess response to the adenoviral or inactivated vaccines. CONCLUSIONS: Our meta-analysis demonstrated that patients with IMIDs have a reduced response to mRNA COVID-19 vaccines. These results suggest that IMID patients receiving mRNA vaccines should complete the vaccine series without delay and support the strategy of providing a third dose of the vaccine.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Sakuraba A, Luna A, Micic D, et al. Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. Gastroenterology. 2021. PMID: 34599933. doi:10.1053/j.gastro.2021.09.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。